Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.

Cancer science - 1 Mar 2012

Achmad Arifudin, Hanaoka Hirofumi, Yoshioka Hiroki, Yamamoto Shinji, Tominaga Hideyuki, Araki Takuya, Ohshima Yasuhiro, Oriuchi Noboru, Endo Keigo

Abstract excerpt

Overexpression of epidermal growth factor receptor (EGFR) is common in colorectal cancer. However, cetuximab as an EGFR-targeting drug is useful only for a subset of patients and currently no single predictor other than V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status has been established. In the present study, we investigated cetuximab accumulation in colorectal tumors and major organs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cetuximab

Share to HT29 Cells

Share to Positron-Emission Tomography

Share to Radiopharmaceuticals

Share to Tissue Distribution

Share to Transplantation, Heterologous

Source

Open in PubMed Open full text

Identifiers

PMID: 22126621
DOI: 10.1111/j.1349-7006.2011.02166.x
PMCID: PMC7713619

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.PMID 22126621Read ↗

89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.Semantic proximity Read ↗

Panitumumab in the treatment of colon cancer: A biomarker dilemma.Semantic proximity Read ↗

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.Semantic proximity Read ↗

Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip.Semantic proximity Read ↗

Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation.Semantic proximity Read ↗

KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.Semantic proximity Read ↗

Efficacy of Bivalent CEACAM6/4-1BBL Genetic Vaccine Combined with Anti-PD1 Antibody in HCT116 Xenograft MiceSemantic proximity Read ↗

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.Semantic proximity Read ↗

Correlation between PET/CT parameters and KRAS expression in colorectal cancer.Semantic proximity Read ↗

Imaging human pancreatic cancer xenografts by targeting mutant KRAS2 mRNA with [(111)In]DOTA(n)-poly(diamidopropanoyl)(m)-KRAS2 PNA-D(Cys-Ser-Lys-Cys) nanoparticles.Semantic proximity Read ↗

Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.